Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

A fine-tuned activation and deactivation of proteases and their inhibitors are involved in the
execution of the inflammatory response. The zymogen/proenzyme plasminogen is converted …

In response to vessel injury (or other pathological conditions), the hemostatic process is
activated, resulting in a fibrous, cellular-rich structure commonly referred to as a blood clot …

This review focuses on fibrin, starting from biological mechanisms (its production from
fibrinogen and its enzymatic degradation), through its use as a medical device and as a …

Enzyme therapies are attracting significant attention as thrombolytic drugs during the current
scenario owing to their great affinity, specificity, catalytic activity, and stability. Among various …

Intravenous administration of fibrinolytic drugs is the standard treatment of acute thrombotic
diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short …

The development of safe and efficacious enzyme-based human therapies has increased
greatly in the last decades, thanks to remarkable advances in the understanding of the …

With the accelerated development of nanotechnology in recent years, nanomaterials have
become increasingly prevalent in the medical field. The poly (lactic acid–glycolic acid) …

Stachybotrys microspora triprenyl phenol (SMTP) is a large family of small molecules
derived from the fungus S. microspora. SMTP acts as a zymogen modulator (specifically …

Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent
neuronal death, represents one of the main causes of disability in developed countries …